CytoMed Therapeutics Ltd (GDTC)
$0.86+$0.08 (+10.02%) Latest session
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 4 | 400,000 | $600K |
3 Form 4 filings on record, the earliest from Jun 15, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Chee Kong Choo - Director | Open-market purchase | ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED | 100,000 | $1.50 | $150K | |
| Chee Kong Choo - Director | Open-market purchase | ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED | 100,000 | $1.50 | $150K | |
| Chee Kong Choo - Director | Open-market purchase | ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED | 100,000 | $1.50 | $150K | |
| Chee Kong Choo - Director | Open-market purchase | ORDINARY SHARES OF CYTOMED THERAPEUTICS LIMITED | 100,000 | $1.50 | $150K | |
| Chee Kong Choo - Director | Open-market purchase | Ordinary Shares, no par value per share | 112,000 | $1.15 | $129K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| mDR Ltd | 10% Stockholder | 117,337 | $103K | View on EDGAR | |
| - | - | - | - | View on EDGAR |
CytoMed Therapeutics Ltd (GDTC) had 2 insider filings in the last 90 days, with the most recent on 2026-07-25. The full record for GDTC runs to 3 Form 4 filings, the earliest from 2026-06-15. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
4 insider purchases of GDTC were filed in the last 90 days, totaling $600K.
No insider sales of GDTC were filed in the last 90 days.
This page tracks GDTC Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add GDTC to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
